JG
PDLI

Jefferies Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Jefferies Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-30,000
Closed -$224K – 2683
2014
Q3 		$224K Buy
+30,000
New +$279K ﹤0.01% 1767

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jefferies Group's PDLI Position: Q1 2020 in Review

Jefferies Group sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 19,745 shares — an estimated $64K sold.

Jefferies Group first reported a position in PDLI in Q3 2013 and held it in 7 quarters. The position peaked at $163K in Q2 2018. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

  • Jefferies Group reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • Jefferies Group sold 19,745 PDL BioPharma, Inc. shares in Q1 2020, an estimated $64K.
  • Jefferies Group first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 7 quarters.
  • Jefferies Group's PDL BioPharma, Inc. position peaked at $163K in Q2 2018.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.